Cervical Intraepithelial Articles & Analysis
5 news found
In the fourth quarter, we completed enrollment of REVEAL2, our second global Phase 3 clinical trial of VGX-3100 for cervical pre-cancer. In addition, we recently completed enrollment in our Phase 1/2 clinical trial for INO-3107, our DNA immunotherapy for the rare disease recurrent respiratory papillomatosis (RRP), which received orphan drug designation from the U.S. ...
HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and preliminary efficacy of VTP-200, Vaccitech’s immunotherapy for high-risk HPV infection and associated low-grade cervical intraepithelial neoplasia. The study plans to enroll 105 women with high-risk HPV infection and will take place at clinical sites ...
This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability and efficacy of VGX-3100 to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL) using the company's proprietary CELLECTRA® 5PSP device. ...
Groningen, the Netherlands - 3 February 2017 - ViciniVax, a Dutch biopharmaceutical company in Groningen, announced today the treatment of the first patient with Vvax001 in a Phase I study in patients with a history of cervical intraepithelial neoplasia (CIN) 2 and 3 or cervical cancer. The Phase I study is an investigator-initiated Phase I ...
The national HPV vaccination program will complement the cervical cancer screening program in Bhutan that has proven successful in recent years. ...